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ismantling Mandates in
he Treatment of Heart Failure*
arl V. Leier, MD
olumbus, Ohio
he Studies Of Left Ventricular Dysfunction (SOLVD)
rial is a landmark study in the management of heart failure.
he treatment limb of this trial (1) demonstrated unequiv-
cally that long-term administration of the angiotensin-
onverting enzyme (ACE) inhibitor enalapril reduced mor-
ality and hospitalization in patients with New York Heart
ssociation functional class II and III heart failure on
tandard background therapy and thus, greatly extended the
opulation base for proven ACE inhibitor benefit beyond
hat of the severe functional class IV patients studied in the
ooperative North Scandinavian Enalapril Survival Study
CONSENSUS) trial (2). The prevention limb of the
OLVD trial then also demonstrated ACE inhibitor ben-
fit in patients with left ventricular (LV) systolic dysfunction
ith minimal to no symptoms (3).
See page 1825
Standard background therapy at the time (1980 to 1990)
onsisted of diuretic agents, digoxin, and in about 50% of
atients, some type of vasodilator (nitrate, hydralazine, or
alcium-channel blocker) (1). The results of the SOLVD
rial, the CONSENSUS trial, and later, the Vasodilator-
eart Failure Trial (V-HeFT II) (4) provided the impetus
o appropriately recommend that ACE inhibitors become a
ajor component of background therapy in the manage-
ent of all stages of LV systolic dysfunction and heart
ailure. A number of large controlled trials added patients
ith myocardial infarction as benefactors of chronic ACE
nhibitor therapy (5–8).
The widespread application of ACE inhibitor therapy in
eart failure became mired in the usual complex inertia of
ringing trial-proven (evidence-based) treatments to clinical
ractice. Five years after U.S. Food and Drug Administra-
ion approval, ACE inhibitor utilization in heart failure was
elow 50%, and below 75% at 10 years, of an estimated 85%
o 90% eligible patients with this condition; an astoundingly
isappointing record in an era whose Paleolithic tools still
onsisted of diuretic agents, digoxin, and a few vasodilators.
arious methods (e.g., review articles, conferences, guide-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.T
From the Davis Heart-Lung Research Institute, The Ohio State University,
olumbus, Ohio.ines) were used to promote (“get the word out”) widespread
se of ACE inhibitor in heart failure. One such tool was
eclaring ACE inhibitors as “mandated” therapy for heart
ailure. Although it is difficult to find this term in print, it
ecame the routine part of the terminology (along with
paradigm shift”) in all lectures and conferences addressing
eart-failure management. Guidelines for managing LV
ystolic dysfunction and heart failure now uniformly include
CE inhibitors as the essential (and typically, the primary)
omponent of standard background therapy for heart failure
9–11).
With the introduction and proven benefits of beta-
drenergic blockers and angiotensin receptor blockers
ARBs) in heart failure, do ACE inhibitors still merit their
andated position as standard background therapy, simply
ecause these agents got there first? Certainly, the position
f digoxin on the list of standard background therapies has
aded somewhat, and ARB therapy has moved into equiv-
lency with ACE inhibitors and, when properly dosed, has
better side-effect profile (12–14). As uncomfortable as it is
hen anything standard is threatened, should the sands of
tandard background therapy in heart failure be shifting?
Clinically experienced heart-failure specialists have known
or decades that the optimal treatment plan for this condition
s highly individualized; it is unlikely that any 2 of 100 patients,
ven at the same institution, will be receiving the same doses of
he same medications. The same specialists have also had to
eal with the clinical impression that certain patients with
eart failure clinically respond better when beta-blockade is
ntroduced before ACE inhibitors (or ARBs); for now, such
atients include the euvolemic hyperadrenergic patient and
ost patients with chemotherapy-induced (doxorubicin, cyclo-
hosphamide) cardiomyopathy (15). Even in these situations,
t is often challenging to convince house staff and junior faculty,
ho are now expected to closely follow the mandated guide-
ines of their hospital or health maintenance organization, that
t may be acceptable to start beta-blockade and advance its dose
o optimal levels before adding the ACE inhibitor.
Although their opinions are rarely verbalized in public,
any experienced heart-failure specialists likely believe that
ad beta-blockers (and ARBs) arrived at the scene first,
CE inhibitors would now be viewed as second-line agents
r as optional add-on therapy for patients on the back-
round therapy of beta-blockade, diuretic agents, spirono-
actone where indicated, probably an ARB, and perhaps
igoxin. Herein lies the impact of the scientifically humble,
et piercing report in this issue of the Journal by Sliwa et al.
16) at the University of Witwatersrand, Johannesburg.
Sliwa et al. (16) found that certain clinical and laboratory
esponses were substantially better if beta-blockade (carve-
ilol) preceded, rather than followed, an ACE inhibitor
perindopril) in the initial sequence of the long-term (6 and
2 months) treatment plan of patients with New York
eart Association functional class II and III heart failure.
he more favorable responses associated with starting with
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Editorial Comment November 2, 2004:1831–3eta-blockade first include better functional class, higher
chievable doses of beta-blocker drug, reduced diuretic-
gent requirement, larger increment of LV ejection fraction
y multigated angiography (nuclear), better echocardio-
raphic parameters of diastolic function and reverse remod-
ling, and lower levels of plasma NT-pro-brain natriuretic
eptide. In none of the measured end points did initiating
CE inhibitors first fare better than starting treatment with
eta-blockade. And although some favorable responses were
till achieved by adding an ACE inhibitor after six months
f beta-blockade, the additional improvement for most of
hese parameters (e.g., LV ejection fraction, brain natri-
retic peptide) was relatively modest in degree.
There are a number of possible scientific and theoretical
easons the results of this study make sense. Beta-blockade
lunts the hyperactivation and effects of the major neuroen-
ocrine forces in heart failure, namely the sympathetic
ervous system and the renin-angiotensin-aldosterone sys-
em. The ACE inhibitors mostly affect the latter. Beta-
lockade reduces heart rate to a far greater degree, with a
onsequent fall in myocardial oxygen consumption, while
ugmenting coronary perfusion by increasing diastolic time
17). Beta-blockade alone impedes the direct toxic effects on
he myocardium of the elevated circulating catecholamines
n heart failure. Beta-blockade consistently effects a better
mprovement in ejection fraction and reverse remodeling
han that attained with chronic ACE inhibitor therapy.
chieving a higher dose of beta-blockade in the patients
ho were started on beta-blockers first (while both groups
rrived at the same optimal ACE inhibitor dose) likely
ontributed to the more impressive response in this treat-
ent group.
Most clinically experienced heart-failure specialists will
ot be surprised by the results of the Sliwa et al. study (16),
nd most should be pleased that this study was performed.
ecause of our preoccupation with ethics (often at the
xpense of science and, ironically in this case, the well-being
f patients), it is unlikely that a similar study could have
een performed in the U.S. In this “land of the free,” we
ave unknowingly restricted our “freedom to choose” by
andating treatment and background therapies. It is reas-
uring to know that wisdom and rational thought remain
ntact beyond our borders.
Indeed, the Sliwa et al. study (16) has enormous limita-
ions, most acknowledged by the authors. The drug, perin-
opril, does not jump to the front of one’s mind when listing
CE inhibitor drugs, but it has been studied in heart failure
ith results that place this compound under the favorable
lass-effects of ACE inhibitors in this condition (18). Using
ther current trials as a guide, the study is small (total n 
8 patients) and it was performed at a single center.
owever, the study is adequately powered statistically for
he end points selected. Blinding of treatment was limited
o the examining physician (to assess functional class) and to
hose measuring end points. The study was not powered to
ddress survival and other responses (e.g., exercise perfor- mance, dysrhythmias). In their favor, the investigators
isely excluded patients with heart failure secondary to
oronary artery disease, who may have shown an even more
avorable response to beta-blockade and thus would have
een a complicating variable in the interpretation of the
esults. The study was supported by educational grants from
oche Pharmaceuticals and Servier Pharmaceuticals of
outh Africa. In South Africa, Boehringer Ingelheim is the
arketing firm for carvedilol, and Servier performs the same
ole for perindopril.
Based on the results of the Sliwa et al. study (16), it is still
ot appropriate to conclude that the treatment plan for all
atients with heart failure should now begin with a diuretic
gent, beta-blockade, and in some instances spironolactone,
ith subsequent addition of an ACE inhibitor or ARB (and
ossibly digoxin). A large multicenter trial(s) incorporating the
nd points of survival and hospitalization would have to be
erformed to verify the results of the Sliwa et al. study (16), to
etermine the proper sequence of drug administration, and, in
his era of polypharmacy, to define the necessary contributing
omponents on the growing list of potentially beneficial med-
cations. The Sliwa et al. study (16) could possibly provide the
nspiration and impetus to launch such an investigation.
arenthetically, it is pleasing to see that some investigators are
till willing to address important clinical and scientific ques-
ions outside the dominant multiyear, multicenter, and multi-
housand-patient trial.
Whether the ACE inhibitor will lose its coveted position
s an obligatory component of background therapy for heart
ailure, or whether this question will ever be addressed
gain, remains to be seen. The results of the Sliwa et al.
tudy (16) should certainly place this question in the minds
f physicians treating this reasonably challenging, complex
ondition. In the least, the report should discourage the
oncept of “mandated” background therapy and replace it
ith “recommended” options. This shift will allow the
elivery of better management to the individual patient and
oster a more ideal population base for the development and
tudy of newer therapies without being modified or masked
y an entrenched, and perhaps less effective, therapy. For-
unately, combination hydralazine-nitrate was not man-
ated as an obligatory background therapy after the
-HeFT trial (19).
In contrast to most other disciplines dealing with com-
lex, ill, and often end-stage patients (e.g., oncology,
nfectious diseases, nephrology), heart-failure specialists
ave been eager to mandate therapies. It is time to mature
s a discipline and move beyond dogmatic declarations and
andates.
eprint requests and correspondence: Dr. Carl V. Leier, Davis
eart-Lung Research Institute, 473West 12th Avenue, The Ohio
tate University, Columbus, Ohio 43210. E-mail: leier-1@
edctr.osu.edu.
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